INDICATIONS AND USAGE
TEFLARO® (ceftaroline fosamil)
is indicated in adult and pediatric patients (at least 34 weeks gestational age and 12 days postnatal age and older)
for the treatment of
acute bacterial skin and skin structure infections (ABSSSI)
caused by susceptible isolates of the
following Gram-positive and Gram-negative microorganisms:
Staphylococcus aureus (including methicillin-susceptible
and -resistant isolates),
Streptococcus agalactiae, Escherichia coli,
TEFLARO is also indicated in adult and pediatric patients 2 months of age and older for the treatment of
community-acquired bacterial pneumonia (CABP)
caused by susceptible isolates of the following Gram-positive
and Gram-negative microorganisms: Streptococcus pneumoniae
(including cases with concurrent bacteremia),
(methicillin-susceptible isolates only),
influenzae, Klebsiella pneumoniae, Klebsiella oxytoca,
To reduce the development of drug-resistant bacteria
and maintain the effectiveness of TEFLARO and other antibacterial
drugs, TEFLARO should be used to treat only ABSSSI or CABP that
are proven or strongly suspected to be caused by susceptible
bacteria. Appropriate specimens for microbiological examination
should be obtained in order to isolate and identify the causative
pathogens and to determine their susceptibility to ceftaroline.
When culture and susceptibility information are available, they
should be considered in selecting or modifying antibacterial
therapy. In the absence of such data, local epidemiology and
susceptibility patterns may contribute to the empiric selection of therapy.
IMPORTANT SAFETY INFORMATION
TEFLARO is contraindicated in patients with known serious hypersensitivity to ceftaroline or
other members of the cephalosporin class. Anaphylaxis has been reported with ceftaroline.
Warnings and Precautions
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions
have been reported with beta-lactam antibacterial drugs. Before therapy with TEFLARO is instituted,
careful inquiry about previous hypersensitivity reactions to other cephalosporins, penicillins, or
carbapenems should be made. Maintain clinical supervision if this product is to be given to a
penicillin- or other beta-lactam-allergic patient, because cross sensitivity among beta-lactam
antibacterial agents has been clearly established.
If an allergic reaction to TEFLARO occurs, discontinue TEFLARO and institute appropriate treatment
and supportive measures.
Clostridium difficile-Associated Diarrhea
Clostridium difficile-Associated Diarrhea (CDAD) has been reported for nearly all systemic
antibacterial agents, including TEFLARO, and may range in severity from mild diarrhea to fatal colitis.
Careful medical history is necessary because CDAD has been reported to occur
more than 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed,
antibacterials not directed against C. difficile should be discontinued, if possible.
Direct Coombs' Test Seroconversion
In adults, seroconversion from a negative to a positive direct Coombs' test result occurred in 120/1114
(10.8%) of patients receiving TEFLARO and 49/1116 (4.4%) of patients receiving comparator drugs in the four
pooled adult Phase 3 trials.
In children, seroconversion from a negative to a positive direct Coombs' test result occurred in 42/234
(17.9%) of patients receiving TEFLARO and 3/93 (3.2%) of patients receiving comparator drugs in the three
pooled pediatric trials.
No adverse reactions representing hemolytic anemia were reported in any treatment group. If anemia develops
during or after treatment with TEFLARO, drug-induced hemolytic anemia should be considered. If drug-induced
hemolytic anemia is suspected, discontinuation of TEFLARO should be considered and supportive care should be
administered to the patient if clinically indicated.
Development of Drug-Resistant Bacteria
Prescribing TEFLARO in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit
to the patient and increases the risk of the development of drug-resistant bacteria.
Adverse Reactions in Adults
In the four pooled adult Phase 3 clinical trials, serious adverse reactions occurred in 98/1300 (7.5%)
of patients receiving TEFLARO and 100/1297 (7.7%) of patients receiving comparator drugs. Treatment discontinuation due to
adverse reactions occurred in 35/1300 (2.7%) of patients receiving TEFLARO and 48/1297 (3.7%) of patients receiving comparator
drugs with the most common adverse reactions leading to discontinuation being hypersensitivity for both treatment groups at a rate of
0.3% in the TEFLARO group and 0.5% in the comparator group.
The most common adverse reactions occurring in >2% of patients receiving TEFLARO in the adult pooled Phase
3 clinical trials were diarrhea (5%) nausea (4%), and rash (3%).
Adverse Reactions in Pediatrics
In the three pooled pediatric clinical trials, serious adverse reactions occurred in 10/257 (4%) of patients
receiving TEFLARO and 3/102 (3%) of patients receiving comparator drugs. Treatment discontinuation due to adverse
reactions occurred in 10/257 (3.9%) of patients receiving TEFLARO and 2/102 (2%) of patients receiving comparator
drugs with the most common adverse reaction leading to discontinuation being rash in 2/257 (0.8%) of patients
treated with TEFLARO.
The most common adverse reactions occurring in ≥3% of patients receiving TEFLARO in the pooled pediatric clinical
trials were diarrhea (8%), rash (7%), vomiting (5%), pyrexia (3%) and nausea (3%).
No clinical drug-drug interaction studies have been conducted with TEFLARO. There is minimal potential for drug-drug
interactions between TEFLARO and CYP450 substrates, inhibitors, or inducers; drugs known to undergo active renal
secretion; and drugs that may alter renal blood flow.
Use in Specific Populations
There have been no adequate and well-controlled studies with TEFLARO in pregnant or nursing women. TEFLARO should
only be used if the potential benefit justifies the potential risk in these populations.
Safety and effectiveness of TEFLARO for the treatment of ABSSSI in pediatric patients less than 34 weeks gestational age and less than 12 days postnatal age have not been established.
Safety and effectiveness for the treatment of CABP in pediatric patients below the age of 2 months have not been established as no data are available.
Because elderly patients, those ≥65 years of age, are more likely to have decreased renal function and ceftaroline
is excreted primarily by the kidney, care should be taken in dose selection in this age group and it may be useful to monitor
renal function. Dosage adjustment for elderly patients should therefore be based on renal function.
Dosage adjustment is required in adult patients with moderate (CrCl >30 to ≤50 mL/min) or severe (CrCl ≥15 to ≤30 mL/min)
renal impairment and in patients with end-stage renal disease (CrCl <15 mL/min). There is insufficient information
to recommend a dosage regimen for pediatric patients with CrCl <50 mL/min/1.73m2.
The pharmacokinetics of ceftaroline in patients with hepatic impairment have not been established.
Please also see full Prescribing Information.